Prolonged third complete remission after busulfan, thiotepa, and autologous stem cell transplant in a primary central nervous system lymphoma patient

Primary central nervous system lymphoma (PCNSL) remains a therapeutic challenge due to impaired drugs diffusion as a result of the blood‐brain barrier and high risk of relapse. Patients with good performance status, chemo‐sensitive disease, and eligible for autologous stem cell transplant (ASCT) may...

Descripción completa

Detalles Bibliográficos
Autores principales: Camus, Vincent, Dubois, Sydney, Lepretre, Stéphane, Jardin, Fabrice, Tilly, Hervé
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099056/
https://www.ncbi.nlm.nih.gov/pubmed/30147874
http://dx.doi.org/10.1002/ccr3.1630
Descripción
Sumario:Primary central nervous system lymphoma (PCNSL) remains a therapeutic challenge due to impaired drugs diffusion as a result of the blood‐brain barrier and high risk of relapse. Patients with good performance status, chemo‐sensitive disease, and eligible for autologous stem cell transplant (ASCT) may benefit from salvage therapy and therapeutic intensification that may allow long‐term remission.

Ejemplares similares